EK
Co-Founder & Director, Research & Development
Get the full picture
Sign in to uncover key details.
Vasocure
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
325 Winthrop St, Brooklyn, New York, 112...Website
www.vasocuretherapeutics.comRevenue
<$5 MillionIndustry
About Vasocure
Vasocure is a novel therapeutics company focused on developing innovative treatments for vascular diseases, particularly through its first-in-class drug, Pedifin, which targets neointimal disease and atherosclerosis. The company has a diverse pipeline with 62 candidates across nephrology, cardiology, and oncology, aiming to address significant medical needs in these areas. Vasocure's precision medicine approach seeks to enhance treatment efficacy and improve patient outcomes, especially for those suffering from chronic kidney disease and related conditions. With ongoing clinical trials, Vasocure is committed to providing better therapeutic options for patients worldwide.Explore more
Vasocure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Vasocure
Compare insights from companies similar to Vasocure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vasocure Tech Stack
A closer look at the technologies used by Vasocure
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vasocure
Sign Up For FreeTo access detailed company insights
Vasocure is a novel therapeutics company focused on developing innovative treatments for vascular diseases, particularly through its first-in-class drug, Pedifin, which targets neointimal disease and atherosclerosis. The company has a diverse pipeline with 62 candidates across nephrology, cardiology, and oncology, aiming to address significant medi... Read More
